all report title image

COLORECTAL CANCER SCREENING MARKET ANALYSIS

Colorectal Cancer Screening Market, By Screening Tests (Stool-based Tests, Colonoscopy, CT Colonography , Flexible Sigmoidoscopy, Others), By End User (Hospitals, Specialty Clinics, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : May 2024
  • Code : CMI5098
  • Pages :181
  • Formats :
      Excel and PDF
  • Industry : Clinical Diagnostic

Colorectal Cancer Screening Market Size and Trends

Global colorectal cancer screening market is estimated to be valued at USD 15.44 Bn in 2024 and is expected to reach USD 24.95 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031.

Colorectal Cancer Screening Market Key Factors

To learn more about this report, request sample copy

Global colorectal cancer screening market is expected to witness considerable growth due to increasing prevalence of colorectal cancer worldwide. Rising awareness about periodic screening and improvements in screening technology are also expected to drive the market growth. Moreover, favourable government initiatives and reimbursement policies boosts the adoption of colorectal cancer screening, and thus, driving the market growth. Thus, increasing focus on early detection of colorectal cancer can boost demand for screening tests.

Increasing Prevalence of Colorectal Cancer

Increasing prevalence of colorectal cancer across the globe is expected to drive the global colorectal cancer screening market growth over the forecast period. For instance, in the U.S., colorectal cancer is the third leading cause of cancer-related deaths in men and in women.

 According to the American Cancer Society, in 2022, there will be around 106,180 new cancer cases diagnosed and 52,580 cancer deaths in the U.S. Thus, increasing prevalence of colorectal cancer boosts demand for colorectal cancer screening in this region.

/p>Increasing Demand for Colorectal Cancer Screening Tests

Increasing demand for colorectal cancer screening tests is expected to drive the global colorectal cancer screening market growth over the forecast period. For instance, in May 2022, Guardant Health, Inc., a healthcare company, announced the availability of Shield, the company’s first blood-based test for the detection of early-stage colorectal cancer. The test is intended for adults aged 45 years and older and those who are not up to date with recommended screening guidelines, show no symptoms, and are at average risk for colorectal cancer.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.